Applications published 24 December 2008

Published: 6-Feb-2009

Compsns, methods and kits using adenosine in combination for diagnosis and treatment
Adenobio 2004139*

• Delivery means
AGT Sciences 2004140*

• An efficient method for loading amphoteric liposomes with nucleic acid active substances
novosom 2004141*

• Enhancing solubility and dissolution rates of poorly soluble drugs
KU Leuven Research and Development 2004142*

• Compsns including relatively water insoluble/unwettable drugs and methods for using same
Allergan 2004143*

• Method for obtaining hollow particles
Stichting Katholieke Universiteit 2004144*

• Alkylene-dicarboxylate-containing biodegradable poly(ester amides) and methods of use
Medivas 2004145*

• A tablet of paracetamol containing an encapsulated flavorant
Reckitt Benckiser Healthcare (UK) 2004146*

• Pharmaceutical compsn containing sympathomimetic amine
Wyeth 2004147*

• Pharmaceutical formulations: salts of 8-[{1-(3,5-bis (trifluoro-methyl)phenyl)-E thoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4,5]decan-2-one and treatment methods using the same
Schering 2004148*

• Pharmaceutical compsns containing leflunomid
Tiefenbacher Pharmachemikalien Alfred E Tiefenbacher 2004149*

• Sustained release pharmaceutical compsn on the basis of a release system comprising an acid-soluble polymer and a pH-dependent polymer
Panacea Biotec 2004150*

• Oral pharmaceutical coated compsn for pulsatile release
Novartis 2004151*

• Multi-membrane immunoisolation system for cellular transplant
Encapsulife 2004152*

• Impact of calcium phosphate complex on dental caries
Cadbury Adams 2004153*

• Inhibitors of protein aggregation
Wista Laboratories 2004155*

• Compsns for transfection of oligonucleotides active for biological and therapeutic applications
Polyplus-Transfection 2004156*

• Use of GPR119 receptor agonists for increasing bone mass and for treating osteoporosis, as well as combination therapy relating thereto
Arena Pharmaceuticals 2004157*

• Use of inhibitors of jun N-terminal kinases to treat glaucoma
Alcon 2004158*

• Autoimmune conditions and NADPH oxidase defects
Biovitrum 2004159*

• Oral compsn with an antiageing effect on the skin
Unilever 2004160*

• Oral compsn comprising DHA and genistein for enhancing skin properties
Unilever 2004161*

• Use of polyamines in the treatment of psoriasis
Bioforskning Pharma 2004162*

• Combinations comprising MTOR inhibitors for treating cancer
Novartis Pharma AG; Novartis Pharma GmbH 2004163*

• Pharmaceutical compsn for treating or preventing degenerative and inflammatory diseases
Neurotech 2004164*

• Synergistic combinations of anticancer agents for treating cancer
Novartis Pharma 2004165*

• Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases
La Jolla Pharmaceutical 2004166*

• Renin inhibitors for the treatment of hypertension
Novartis AG; Novartis Pharma 2004167*

• Stable oral pharmaceutical compsn containing thyroid hormone receptor agonists
Karo Bio; Bristol-Myers Squibb 2004168*

• Oral compsn comprising a polyunsaturated fatty acid and salicylic acid for obtaining an antiinflammatory effect in skin
Unilever 2004169*

• Treatment of haematological malignancies with FTS and a BCR-ABL tyrosine kinase inhibitor
Ramot at Tel-Aviv University 2004170*

• Treatments using citrulline
Nestec; Novartis Pharma 2004171*

• Drug delivery methods, structures, and compsns for naso-lacrimal system
QLT Plug Delivery 2004172*

• Use of aminapthone for the preparation of a medicament for treating arteriophaties
Fondazione IRCCS Istituto di Rivero e Cura a Carattere Scientifico di Natura Pubblica Ospedale Maggiore Policlinico Mangiagalle e Regina Elena 2004173*

• Napthalenedione compounds
Sunten Phytotech 2004174*

• Anticancer activity augmentation compounds and formulations and methods of use thereof
Bionumerik Pharmaceuticals 2004175*

• Use of N-(dibenz(b,f)oxepin-10-ylmethyl) N-methyl-N-prop-2-ynylamine (omgapil) for the prophylaxis and/or treatment of congenital muscular dystrophy or myopathy resulting from collagen VI deficiency
Santhera Pharmaceuticals (Schweiz) 2004176*

• Nitrofuran compounds for the treatment of cancer and angiogenesis
Women and Infants Hospital of Rhode Island 2004177*

• Pharmaceutical combination compsn comprising at least one PKC inhibitor and at least one JAK3 kinase inhibitor for treating autoimmune disorders
Novartis 2004178*

• Medicament, cosmetic or food product comprising an indol compound, the use thereof and the method of isolation thereof from sauerkraut
G.I.M.-Gesellschaft für Innovative Medizin 2004179*

• Use of a kinase inhibitor for the treatment of particular resistant tumours
Nerviano Medical Sciences 2004180*

• Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
The Regents of the University of California 2004181*

• Benzimidazoles which have activity at M1 receptor and their uses in medicine
Glaxo Group 2004182*

• Mazindol combination in the treatment of attention deficit/hyperactivity
Assistance Publique – Hôpital de Paris 2004183*

• Combinations of therapeutic agents for treating cancer
Novartis 2004184*

• Novel heterocyclic diphenyl ethers
Bexel Pharmaceuticals 2004185*

• Varenicline standards and impurity controls
Pfizer Products 2004186*

• Dietary supplement for healing or regressing symptoms of gastroesophageal reflux disease, gastritis and ulcers
De Souza Pereira, Ricardo 2004187*

• Benzoimidazol-2-yl pyrimidines as modulators of the histamine H4 receptor
Janssen Pharmaceutica 2004188*

• Thiazolidinedione derivatives as P13 kinase inhibitors
SmithKline Beecham 2004189*

• Non-codeine opioid analgesic process and formulations
Graydon, Cameron 2004190*

• Trimetazidine for use in the treatment of fibromyalgia syndrome and related conditions
Mintails 2004191*

• Modified macrophage migration inhibitory factor inhibitors
The Feinstein Institute for Medical Research 2004192*

• Ophthalmic compsns for treating ocular hypertension
Merck 2004193*

• Azoxystrobin formulations
Syngenta Participations 2004194*

• Use of 5H-dibenz/B,F/azepine-5-carboxamide derivatives in the treatment of neuropathic pain and neurological disorders
Bial - Portela & Ca 2004195*

• Ocular allergy treatments
Viskaton Pharmaceuticals 2004196*

• Light activated antiviral materials and devices and methods for decontaminating virus infected environments
North Carolina State University; Emory University 2004197*

• Method of treating paediatric patients with corticosteroids
Medicis Pharmaceutical 2004198*

• Treatment of menopause-associated symptoms
Besins International Healthcare 2004199*

• Methods for prevention and treatment of conditions arising from local oestrogen deficiency
Wyeth 2004200*

• Use of a growth-stimulating protein
Westermarck, Jukka; Puustinen, Pietri; Junttila, Melissa 2004202*

• Formulations of low-dose diclofenac and beta-cyclodextrin
Javelin Pharmaceuticals; Wright, Curtis 2004203*

• Treatment of neurodegenerative diseases
Velacor Therapeutics 2004204*

• Inorganic selenium for treatment of benign tumours
Velacor Therapeutics 2004205*

• Phospholipid complexes of olive fruits or leaves extracts having improved bioavailability
Indena 2004206*

• Active substance fractions for formulations for the therapy and prophylaxis of inflammatory diseases
Hochschule Anhalt; ESA Patentverwertungsagentur Sachsen-Anhalt 2004207*

• Compsn and method for stabilising corneal tissue after refractive surgery
Euclid Systems 2004209*

• Antiangiogenic peptide and therapeutic uses thereof
Instituto nazionale per la ricerca sul cancro 2004210*

• Dosing regimes for LH or HCG and EPO for treatment of neurological disorders
Stem Cell Therapeutics 2004211*

• Continuous dosing regimens for neural stem cell proliferating agents and neural stem cell differentiating agents
Stem Cell Therapeutics 2004212*

• GLP-1 peptide agonists
Novo Nordisk 2004213*

• Methods for local treatment with Factor VII
Drugrecure ApS 2004214*

• Anti-microbial compsns comprising a cationic peptide and a glycylclycine endopeptidase
The University Court of the University of St Andrews 2004215*

• Agent for the treatment of hormone-dependent disorders and uses thereof
BioPharmacia 2004216*

• Vaccine for a therapeutic or a prophylactic treatment of myasthenia gravis
Curavac 2004217*

• HER-2/NEU multi-peptide vaccine
Bio Life Science Forschungs- und Entiwcklungsges 2004218*

• Reagents and methods for cancer treatment and prevention
The Buck Institute for Age Research 2004219*

Trending Articles

You may also like